Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;39(4):645-650.
doi: 10.5114/ada.2022.118919. Epub 2022 Sep 1.

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus

Aleksandra Frątczak  1 , Karina Polak  1 , Michał Szczepanek  1 , Anna Lis-Święty  1
Affiliations
Review

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus

Aleksandra Frątczak et al. Postepy Dermatol Alergol. 2022 Aug.

Abstract

Inflammation and atherogenic dyslipidaemia are often observed in skin diseases and represent an increased risk of cardiovascular disorders. Proprotein convertase subtilisin/kexin type 9 plays an important role in the regulation of serum low-density lipoprotein cholesterol levels. Its biological role, however, seems to go much beyond the regulation of cholesterol metabolism. The article presents potential pathophysiological links between inflammatory process and lipid disorders based on the example of psoriasis and systemic lupus erythematosus.

Keywords: PCSK9; alirocumab; evolocumab; psoriasis; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. PCSK9 (brown) binds to the low-density lipoprotein receptor (LDL-R) (green), promoting its lysosomal degradation
Figure 2
Figure 2
Mechanism of action for proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies. Monoclonal antibodies against PCSK9 (red) block binding of PCSK9 (brown) to the low-density lipoprotein receptor (LDL-R) (green) and prevent LDL-R degradation, which results in a higher LDL receptor recycling and reduced serum LDL level
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Seidah N, Benjannet S, Wickham L. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928-33. - PMC - PubMed
    1. Abifadel M, Guerin M, Benjannet S, et al. . Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012; 223: 394-400. - PubMed
    1. Cohen J, Pertsemlidis A, Kotowski I, et al. . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-5. - PubMed
    1. Artenstein A, Opal S. Proprotein convertases in helath and disease. N Engl J Med 2011; 365: 2507-18. - PubMed
    1. Siedah N. The proprotein convertases, 20 years later. Methods Mol Biol 2011; 768: 23-57. - PubMed